CereVasc

CereVasc, Inc. is a clinical-stage medical device company dedicated to developing innovative, minimally invasive treatments for patients suffering from neurological diseases. The company's initial product, the eShunt System, is a groundbreaking percutaneous transvenous-transdural access to the central nervous system, intended to be the first minimally invasive treatment for communicating hydrocephalus (CH). This potentially revolutionary approach aims to improve upon the current standard of care, which involves invasive surgical procedures. CereVasc's work is rooted in research and collaboration with leading medical professionals at Tufts Medical Center, and the company holds numerous patents for its technology.

CereVasc's commitment to advancing minimally invasive treatments for neurological diseases is evident in its ongoing clinical trials and partnerships with prominent medical institutions and researchers worldwide. The company's eShunt System has garnered significant attention and investment, with the potential to revolutionize the treatment of hydrocephalus and improve the lives of countless patients. With its focus on innovation and collaboration, CereVasc is poised to make a lasting impact in the field of neurological disease treatment.

CereVasc is a clinical-stage medical device company dedicated to developing novel, minimally invasive treatments for patients with neurological diseases. Their initial product, the eShunt System, is a groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to provide the first minimally invasive treatment for communicating hydrocephalus (CH). CereVasc aims to dramatically improve the care of patients with hydrocephalus by offering a safer and less invasive alternative to traditional surgical procedures.